Crombie C, Raghavan D, Page J, Woods R, Dalley D, Devine R, Rosen M
Br J Urol. 1987 May;59(5):443-6. doi: 10.1111/j.1464-410x.1987.tb04843.x.
Forty-three males with recurrent and metastatic cancer of the prostate were treated with megestrol acetate (160 mg/day orally) after having failed first-line hormonal treatment (orchiectomy or diethylstilboestrol). Thirty-seven patients were evaluated objectively for response, 28 of whom received the drug for more than 6 weeks. One patient had a partial response (National Prostatic Cancer Project criteria) and seven had stable disease. Toxicity was usually mild, although five patients developed a transient rise in liver enzymes and one patient had a grand mal fit. Three patients showed evidence of tumour "flare". Megestrol acetate has only limited efficacy in patients previously treated for prostatic cancer by hormonal manipulation.
43例复发性和转移性前列腺癌男性患者在一线激素治疗（睾丸切除术或己烯雌酚）失败后，接受醋酸甲地孕酮治疗（口服160毫克/天）。对37例患者的反应进行了客观评估，其中28例接受该药物治疗超过6周。1例患者有部分缓解（根据国家前列腺癌项目标准），7例病情稳定。毒性通常较轻，尽管有5例患者肝酶短暂升高，1例患者发生大发作。3例患者出现肿瘤“flare”迹象。醋酸甲地孕酮对先前接受过激素治疗的前列腺癌患者疗效有限。
